| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ilkka Larmo, André de Nayer, Elmar Windhager, Bernhard Lindenbauer, Hans Rittmannsberger, Thomas Platz, A Martin Jones, Charles Altma. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Human psychopharmacology. vol 20. issue 8. 2006-03-28. PMID:16175656. |
efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. |
2006-03-28 |
2023-08-12 |
Not clear |
| György Bartkó, László Fehé. [Pharmacoeconomic review of the use of injectable long-acting risperidone]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology. vol 7. issue 4. 2006-03-28. PMID:16496485. |
health care resource use is significantly reduced in patients with stable schizophrenia or schizoaffective disorder receiving long-acting, injectable risperidone. |
2006-03-28 |
2023-08-12 |
Not clear |
| György Bartkó, László Fehé. [Pharmacoeconomic review of the use of injectable long-acting risperidone]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology. vol 7. issue 4. 2006-03-28. PMID:16496485. |
one factor remained valid for each country: improved adherence arising through the use of long-acting risperidone provides a cost-effective strategy for treating patients with schizophrenia. |
2006-03-28 |
2023-08-12 |
Not clear |
| György Bartkó, László Fehé. [Pharmacoeconomic review of the use of injectable long-acting risperidone]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology. vol 7. issue 4. 2006-03-28. PMID:16496485. |
on the basis of the cost-effectiveness evaluations in different countries long-acting risperidone seems to offer a cost saving treatment option for patient with schizophrenia under hungarian circumstances. |
2006-03-28 |
2023-08-12 |
Not clear |
| Dan Cooper, Jocelyne Moisan, Michel Gaudet, Belkacem Abdous, Jean-Pierre Grégoir. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 50. issue 14. 2006-03-21. PMID:16494259. |
ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. |
2006-03-21 |
2023-08-12 |
Not clear |
| Dan Cooper, Jocelyne Moisan, Michel Gaudet, Belkacem Abdous, Jean-Pierre Grégoir. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 50. issue 14. 2006-03-21. PMID:16494259. |
to assess treatment discontinuation and concomitant use of other antipsychotics among individuals initiated on olanzapine or risperidone for the treatment of schizophrenia. |
2006-03-21 |
2023-08-12 |
Not clear |
| Kathleen S Jarboe, Kimberly Littrell, Karen Tugru. Long-acting injectable risperidone: an emerging tool in schizophrenia treatment. Journal of psychosocial nursing and mental health services. vol 43. issue 12. 2006-03-02. PMID:16422275. |
long-acting injectable risperidone: an emerging tool in schizophrenia treatment. |
2006-03-02 |
2023-08-12 |
Not clear |
| Gopalan Sethuraman, Cindy C Taylor, Mark Enerson, Eduardo Dunayevic. A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. Schizophrenia research. vol 79. issue 2-3. 2006-02-14. PMID:16054802. |
a retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. |
2006-02-14 |
2023-08-12 |
Not clear |
| Gopalan Sethuraman, Cindy C Taylor, Mark Enerson, Eduardo Dunayevic. A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. Schizophrenia research. vol 79. issue 2-3. 2006-02-14. PMID:16054802. |
available studies suggest comparable efficacy of olanzapine and risperidone for the treatment of schizophrenia over the short term. |
2006-02-14 |
2023-08-12 |
Not clear |
| Istvan Bitter, Pal Czobor, Martin Dossenbach, Jan Volavk. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). European psychiatry : the journal of the Association of European Psychiatrists. vol 20. issue 5-6. 2006-02-10. PMID:16084068. |
effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (ic-soho). |
2006-02-10 |
2023-08-12 |
Not clear |
| William G Honer, Allen E Thornton, Eric Y H Chen, Raymond C K Chan, Jessica O Y Wong, Andrea Bergmann, Peter Falkai, Edith Pomarol-Clotet, Peter J McKenna, Emmanuel Stip, Richard Williams, G William MacEwan, Kishor Wasan, Ric Procyshy. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. The New England journal of medicine. vol 354. issue 5. 2006-02-07. PMID:16452559. |
clozapine alone versus clozapine and risperidone with refractory schizophrenia. |
2006-02-07 |
2023-08-12 |
Not clear |
| Alan Hayco. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. PharmacoEconomics. vol 23 Suppl 1. 2006-01-31. PMID:16416758. |
in this article, cost-effectiveness models of long-acting risperidone developed for different countries are discussed in terms of design, data sources and robustness, and the implications of the results for the treatment of schizophrenia are also reviewed. |
2006-01-31 |
2023-08-12 |
Not clear |
| Diana De Graeve, Ann Smet, Angelika Mehnert, Sue Caleo, Houda Miadi-Fargier, Guillermo Jasso Mosqueda, Damien Lecompte, Joseph Peusken. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. PharmacoEconomics. vol 23 Suppl 1. 2006-01-31. PMID:16416760. |
long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a belgian cost-effectiveness analysis. |
2006-01-31 |
2023-08-12 |
Not clear |
| Diana De Graeve, Ann Smet, Angelika Mehnert, Sue Caleo, Houda Miadi-Fargier, Guillermo Jasso Mosqueda, Damien Lecompte, Joseph Peusken. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. PharmacoEconomics. vol 23 Suppl 1. 2006-01-31. PMID:16416760. |
long-acting risperidone appears to represent a favourable first-line strategy for patients with schizophrenia requiring long-term maintenance treatment. |
2006-01-31 |
2023-08-12 |
Not clear |
| P S Chue, Bart Heeg, Erik Buskens, Ben A van Hou. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. PharmacoEconomics. vol 23 Suppl 1. 2006-01-31. PMID:16416762. |
the aim of the present study was to estimate the cost effectiveness of long-acting risperidone in the treatment of high-risk, non-compliant patients with schizophrenia over a 5-year period in canada. |
2006-01-31 |
2023-08-12 |
Not clear |
| P S Chue, Bart Heeg, Erik Buskens, Ben A van Hou. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. PharmacoEconomics. vol 23 Suppl 1. 2006-01-31. PMID:16416762. |
in this model, initiating treatment of high-risk, non-compliant patients with schizophrenia with long-acting risperidone was the dominant strategy. |
2006-01-31 |
2023-08-12 |
Not clear |
| Natalie C Edwards, Julie C Locklear, Marcia F T Rupnow, Ronald J Diamon. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. PharmacoEconomics. vol 23 Suppl 1. 2006-01-31. PMID:16416763. |
cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the usa. |
2006-01-31 |
2023-08-12 |
Not clear |
| Natalie C Edwards, Julie C Locklear, Marcia F T Rupnow, Ronald J Diamon. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. PharmacoEconomics. vol 23 Suppl 1. 2006-01-31. PMID:16416763. |
the availability of long-acting risperidone injection may increase adherence and lead to improved clinical and economic outcomes for individuals with schizophrenia. |
2006-01-31 |
2023-08-12 |
Not clear |
| Natalie C Edwards, Julie C Locklear, Marcia F T Rupnow, Ronald J Diamon. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. PharmacoEconomics. vol 23 Suppl 1. 2006-01-31. PMID:16416763. |
the objective of this study was to assess the cost effectiveness of long-acting risperidone, oral risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, and haloperidol depot in patients with schizophrenia over 1 year from a healthcare system perspective. |
2006-01-31 |
2023-08-12 |
Not clear |
| Natalie C Edwards, Julie C Locklear, Marcia F T Rupnow, Ronald J Diamon. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. PharmacoEconomics. vol 23 Suppl 1. 2006-01-31. PMID:16416763. |
long-acting risperidone may therefore be a cost saving therapeutic option for patients with schizophrenia. |
2006-01-31 |
2023-08-12 |
Not clear |